AIMS AND BACKGROUND: The purpose of the study was to investigate the IL-2/IL-2 receptor system in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Sera from 40 subjects and 80 patients with stage III and IV NSCLC were assayed for soluble interleukin-2 receptor (sIL-2R) and interleukin-2 (IL-2) by the enzyme-linked immunosorbent assay. Circulating CD25+ cells were analyzed by flow cytoflorimetry. The data were related to clinical status by comparing the levels of sIL-2R and IL-2 at diagnosis and during the treatment. RESULTS: The mean sIL-2R concentrations of the NSCLC patients were significantly higher than the control population (P=0.0001); the patients with metastatic disease had significantly higher levels than those with locally advanced disease (P=0.02). No correlation was seen between circulating CD25+ cells and sIL-2R levels. Disease progression was associated with an increase in sIL-2R levels and a decline in IL-2; the sIL-2R/IL-2 ratio showed a gradual increase with tumor progression. CONCLUSIONS: Our study demonstrates in a large series of patients that in advanced NSCLC there is an imbalance of the IL-2/IL-2 receptor system. Furthermore, circulating sIL-2R levels and the sIL-2R/IL-2 ratio may be useful as markers of disease activity and treatment response, suggesting a potential prognostic value.
AIMS AND BACKGROUND: The purpose of the study was to investigate the IL-2/IL-2 receptor system in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Sera from 40 subjects and 80 patients with stage III and IV NSCLC were assayed for soluble interleukin-2 receptor (sIL-2R) and interleukin-2 (IL-2) by the enzyme-linked immunosorbent assay. Circulating CD25+ cells were analyzed by flow cytoflorimetry. The data were related to clinical status by comparing the levels of sIL-2R and IL-2 at diagnosis and during the treatment. RESULTS: The mean sIL-2R concentrations of the NSCLC patients were significantly higher than the control population (P=0.0001); the patients with metastatic disease had significantly higher levels than those with locally advanced disease (P=0.02). No correlation was seen between circulating CD25+ cells and sIL-2R levels. Disease progression was associated with an increase in sIL-2R levels and a decline in IL-2; the sIL-2R/IL-2 ratio showed a gradual increase with tumor progression. CONCLUSIONS: Our study demonstrates in a large series of patients that in advanced NSCLC there is an imbalance of the IL-2/IL-2 receptor system. Furthermore, circulating sIL-2R levels and the sIL-2R/IL-2 ratio may be useful as markers of disease activity and treatment response, suggesting a potential prognostic value.
Authors: Andreas Weigert; Xiang Zheng; Alina Nenzel; Kati Turkowski; Stefan Günther; Elisabeth Strack; Evelyn Sirait-Fischer; Eiman Elwakeel; Ivan M Kur; Vandana S Nikam; Chanil Valasarajan; Hauke Winter; Alexander Wissgott; Robert Voswinkel; Friedrich Grimminger; Bernhard Brüne; Werner Seeger; Soni Savai Pullamsetti; Rajkumar Savai Journal: Nat Commun Date: 2022-10-14 Impact factor: 17.694